STOCKSCOPE

AVITA Medical (ASX: AVH) Strengthens Cohealyx Growth Potential With Six-Month Healing Results as Revenue Surges 53

Danny Aad

Danny Aad

Technology & Biotechnology Specialist | StockScope

Published:4d ago
AVITA Medical (ASX: AVH) Strengthens Cohealyx Growth Potential With Six-Month Healing Results as Revenue Surges 53

AVITA Medical has delivered another encouraging clinical milestone, with six-month results strengthening the case for its Cohealyx wound treatment technology. The findings add to growing commercial momentum, including a 53% increase in quarterly revenue and improving cash flow.

For AVITA Medical Inc. (ASX: AVH), the combination of stronger clinical evidence, expanding product adoption and upgraded revenue guidance raises an important question: could the company be approaching a significant turning point towards sustainable profitability?

Key Numbers

  • 11 days: Median time to skin graft readiness in the Cohealyx I study.
  • 72%: Proportion of patients ready for grafting within two weeks.
  • 88%: Wound healing rate at eight weeks among assessed patients.
  • US$26.1 million: Q3 2026 revenue, up 53% year-on-year.
  • US$92 million to US$94 million: Upgraded full-year 2026 revenue guidance.

Six-Month Results Strengthen Cohealyx's Clinical Case

AVITA Medical's latest announcement, released on 17 November 2026 in Australia, provides complete six-month follow-up results from its Cohealyx I clinical study involving 40 patients with full-thickness wounds.

The findings build on previously reported results showing a mean time to skin graft readiness of 13.6 days, compared with a 28-day historical performance benchmark derived from published studies of other dermal matrices.

Importantly, the latest follow-up provides further evidence of successful wound healing beyond the initial grafting stage.

At eight weeks after grafting, 88% of assessed patients achieved wound healing, with continued progression through 26 weeks.

Mean Vancouver Scar Scale scores improved from 5.2 at 12 weeks to 3.5 at 26 weeks, indicating improved scar characteristics.

No Cohealyx-related adverse events were reported during the follow-up period.

Microscopic examination also demonstrated tissue integration, new blood vessel formation and collagen development.

These results strengthen Cohealyx's clinical credibility, although the relatively small, single-arm study does not establish definitive superiority over competing products.

Revenue Growth Highlights Expanding Commercial Opportunity

What makes this development particularly encouraging is that AVITA Medical is already translating its broader wound care portfolio into meaningful revenue growth.

Third-quarter revenue increased 53% to US$26.1 million, supported by stronger RECELL sales and growing Cohealyx adoption.

RECELL generated US$22.4 million in US quarterly revenue, while Cohealyx contributed US$2.1 million, increasing approximately 21% from the preceding quarter.

Gross margin improved to 84%, demonstrating attractive product economics and greater manufacturing efficiency.

Financial discipline is also improving.

Quarterly net cash use declined to approximately US$600,000 from US$3.2 million in the preceding quarter, despite the company recording a US$6.2 million net loss.

At 30 September 2026, AVITA Medical held US$10.5 million in cash, cash equivalents and marketable securities.

A subsequent US$10 million credit facility drawdown strengthened liquidity, although total borrowings of US$60 million remain an important consideration.

Building a Broader Advanced Wound Care Business

AVITA Medical is expanding its commercial platform through RECELL, Cohealyx and PermeaDerm, targeting different stages of wound treatment.

Its exclusive US marketing and distribution rights for Cohealyx provide access to a complementary product alongside its established RECELL technology.

Hospital adoption is progressing, supported by additional purchasing committee approvals and expanding clinical evidence.

Another potential growth driver emerged on 4 November 2026, when US Medicare authorities finalised updated physician payment values and simplified RECELL billing codes, effective 1 January 2027.

These changes could support wider procedural adoption, although their ultimate revenue contribution remains dependent on clinical demand and hospital purchasing decisions.

Insight: Is AVITA Medical Approaching a Financial Turning Point?

We think AVITA Medical's outlook is becoming increasingly compelling as clinical validation, revenue growth and improving financial discipline reinforce one another. Its 84% gross margin suggests meaningful operating leverage could emerge as sales expand, while Cohealyx provides an additional commercial growth opportunity beyond RECELL. Importantly, declining cash use indicates progress towards a more sustainable operating model. The company remains loss-making and carries substantial debt, but its expanding product portfolio and stronger financial performance provide credible reasons for optimism. Consistent positive cash flow would represent the clearest confirmation of that progress.

What Happens Next?

AVITA Medical has upgraded its full-year 2026 revenue guidance to US$92 million to US$94 million, representing approximately 28% to 31% growth over 2025.

Management has also reaffirmed its expectation of achieving cash flow breakeven during the fourth quarter of 2026.

Delivering that milestone would strengthen confidence in the company's ability to fund future growth through operations.

Looking ahead, expanding Cohealyx adoption, continued RECELL sales growth and updated Medicare reimbursement arrangements could provide further commercial momentum into 2027.

For shareholders, the opportunity now centres on whether AVITA Medical can convert its strengthening clinical and commercial position into sustained profitability, positive cash generation and a more resilient balance sheet.

Danny Aad

Danny Aad

(Technology & Biotechnology Specialist | StockScope)

Danny Aad is an experienced technology executive with a distinguished career spanning more than three decades, including senior leadership positions as Chief Technology Officer (CTO) across the technology and biotechnology sectors. With extensive expertise in technology strategy, digital innovation and the evolving biotechnology landscape, Danny brings a wealth of industry knowledge and technical insight to his analysis of emerging technologies, corporate developments and investment opportunities.

DisclaimerInformation on Stockscope is general in nature and does not constitute financial product advice. It does not take into account your personal objectives, financial situation or needs. Seek independent advice from a qualified financial adviser before making an investment decision. Stockscope and its affiliates do not guarantee the accuracy or completeness of information published on this website. To the extent permitted by law, they accept no liability for any claim, loss or damage arising from its use or reliance on it. Stockscope and its associates may have commercial relationships with companies featured on this website, hold securities in those companies, or receive commissions in connection with capital raisings.

Continue Reading

ASX slides to five-month low as AI sell-off rattles global markets
Market Briefings
Market Briefings

ASX slides to five-month low as AI sell-off rattles global markets

Australian equities: what moved the ASX 200? Australian shares extended their losing streak on Friday, with the S&P/ASX 200 falling 137.8 points, or 1.58%, to close at 8,592.6. This marked...

Mark ElzayedMark Elzayed•
NEXTDC (ASX: NXT) Raises FY27 Earnings Outlook as $140 Million Melbourne Opportunity Remains in Play
Technology
Technology

NEXTDC (ASX: NXT) Raises FY27 Earnings Outlook as $140 Million Melbourne Opportunity Remains in Play

NEXTDC Limited ASX: NXT has delivered an encouraging upgrade to its FY27 earnings guidance, highlighting the strength of its broader data centre business despite electricity supply delays at...

Danny AadDanny Aad•
Trek Metals (ASX: TKM) Hits 40.3% Manganese at Kuro as High-Grade Discovery Opens Up Bigger Potential
Mining
Mining

Trek Metals (ASX: TKM) Hits 40.3% Manganese at Kuro as High-Grade Discovery Opens Up Bigger Potential

A standout 25-metre intersection grading 31.4% manganese has delivered another encouraging result for Trek Metals Limited ASX: TKM, strengthening the exploration potential of its Kuro discov...

Alison ElzayedAlison Elzayed•
EBR Systems (ASX: EBR) Moves Closer to US-Wide Medicare Coverage as Major Growth Opportunity Emerges
Biotech & Health
Biotech & Health

EBR Systems (ASX: EBR) Moves Closer to US-Wide Medicare Coverage as Major Growth Opportunity Emerges

EBR Systems ASX: EBR has taken another significant step towards expanding the commercial reach of its wireless heart pacing technology, with US Medicare authorities proposing national covera...

Danny AadDanny Aad•
Orion Minerals (ASX: ORN) Unlocks US$6.7 Million From Glencore as Major Copper Production Milestone Approaches
Mining
Mining

Orion Minerals (ASX: ORN) Unlocks US$6.7 Million From Glencore as Major Copper Production Milestone Approaches

Orion Minerals ASX: ORN has reached a significant turning point in its copper and zinc development strategy, receiving its first US$6.7 million payment from global mining group Glencore. The...

Alison ElzayedAlison Elzayed•
EMVision Medical Devices (ASX: EMV) Unlocks a 1,700-Hospital Opportunity as Fresh Funding Accelerates Stroke Scanner Development
Biotech & Health
Biotech & Health

EMVision Medical Devices (ASX: EMV) Unlocks a 1,700-Hospital Opportunity as Fresh Funding Accelerates Stroke Scanner Development

EMVision Medical Devices ASX: EMV is building momentum towards a potentially significant commercial breakthrough, with a fresh $306,750 government grant payment supporting the expansion of i...

Danny AadDanny Aad•
Loading more stories...